Prokidney To Present At The 44Th Annual J.P. Morgan Healthcare Conference

2026-01-06 07:31:39

(MENAFN- GlobeNewsWire - Nasdaq) WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the“Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 44^th Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event.

44 ^th Annual J.P. Morgan Healthcare Conference
Date: Wednesday, January 14, 2026
Time: 8:15am PST
Format: Presentation
Webcast: Link

The live webcast will also be accessible through the“Events” section of the Investor Relations tab within ProKidney's website at . Following the completion of the event, a replay will be available for 30 days.

About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney's lead product candidate, rilparencel (also known as REACT^®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit .

ProKidney Contact
Ethan Holdaway
...

Media Contact
Audra Friis
...

Investor Relations Contact
Daniel Ferry
...

MENAFN06012026004107003653ID1110561722

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.